The Federal Trade Commission accuses CVS, Cigna and UnitedHealth of artificially inflating prices on specialty generic drugs by $7.3 billion over six years.
Elisabeth Foley, a woman who lost her hand in a brutal shark attack, is no different. Although her medical team recommended the use of a prosthetic, her health insurance company did not deem it ...
CVS Caremark Rx blasted the findings for cherry picking certain drugs in an effort to push what it called an 'anti-PBM' ...
From 2017 to 2022, the companies marked up prices at their pharmacies by hundreds or thousands of percent, netting them $7.3 ...
FTC report reveals significant markups by top PBMs on specialty drugs, driving $7.3 billion in revenue and raising costs for ...
Self-funded Pennsylvania-based health plan Imagine360 is buying Ardent Health’s third-party administrator (TPA) HealthFirst, ...
Snyders Pharmacy, located in Oregon’s Ace Hardware, announced it has suspended operation of its drive-thru due to lack of ...
The Federal Trade Commission accuses CVS, Cigna and UnitedHealth of artificially inflating prices on specialty generic drugs ...
The practice inflated costs for consumers and insurers on key treatments for cancer, multiple sclerosis, HIV, organ transplants, and other conditions and procedures, the FTC said. The report ...
Pharmacy benefit managers, which serve as the middlemen between drug makers, insurers and pharmacies, reaped $7.3 billion in revenue from marking up the prices of dozens of specialty generic drugs ...
Regulators published their most detailed findings yet on how some of the nation’s largest companies profited from "excess" ...
Health-care companies slid after a profit warning from Eli Lilly. Shares of the obesity-drug maker tumbled after it slashed its projection for fourth-quarter revenue as the market for drugs that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback